Q2 FY24 Financial Highlights
Vision
A pharmaceutical company focused on delivering high quality medicines to patients around the world
LUPIN
United
States
Evolving portfolio and
pipeline in Complex
platforms (Inhalation,
Biosimilars and
Injectables);
Scaled product
platforms in legacy oral,
ophthalmic and
dermatology
Global
Developed
Markets
India Region
Global operational
efficiency and
presence driving
leverage on capital
investment and R&D
across platforms
through markets with
similar regulatory
regimes
(UK, Europe, Canada
and Australia)
Delivering innovative
brands and above
market Growth
through organic and in-
organic means;
establishing strategic
market adjacencies
Other
Emerging
Markets
Global reach and scale as
a partner of choice in
South Africa, Brazil,
Mexico, Philippines;
Enhancing access to
medicines in anti-TB and
in low and middle
income nations
Continuous Improvement Culture
Best in Class Global Quality
ΑΡΙ
Meaningful scale
achieving competitive
costs to serve internal
as well as external
customers and
contribute
meaningfully to Global
Public Health
16View entire presentation